Compare CLLS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLLS | AKBA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | France | United States |
| Employees | N/A | 194 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.8M | 107.0M |
| IPO Year | 2014 | 2014 |
| Metric | CLLS | AKBA |
|---|---|---|
| Price | $0.97 | $0.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $4.45 | $2.67 |
| AVG Volume (30 Days) | 55.6K | ★ 7.4M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.36 |
| 52 Week High | $5.45 | $1.73 |
| Indicator | CLLS | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 33.07 |
| Support Level | N/A | $0.36 |
| Resistance Level | $1.28 | $1.00 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 6.68 |
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.